Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Clolar clofarabine Acute lymphoblastic leukemia Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. Not filed
Columvi glofitamab Relapsed or refractory diffuse large B-cell lymphoma Reimburse with clinical criteria and/or conditions Complete
Combigan Ophthalmic Solution Brimonidine tartrate/timolol maleate Glaucoma List with clinical criteria and/or conditions Complete
COMPLERA Emtricitabine/ rilpivirine/ tenofovir disoproxil fumarate HIV infection List Complete
Constella Linaclotide Irritable bowel syndrome with constipation Do not list Complete
Contrave naltrexone hydrochloride and bupropion hydrochloride Chronic weight management in adults Do not reimburse Complete
Copaxone Glatiramer acetate Clinically Isolated Syndrome (CIS), suggestive of Multiple Sclerosis Do not list Complete
Cortiment Budesonide Ulcerative Colitis Do not reimburse Complete
Corzyna ranolazine Stable angina pectoris, adults Do not reimburse Complete
Cosentyx Secukinumab Plaque psoriasis List with criteria/condition Complete